首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1593536

CAR-T細胞療法市場規模、佔有率和成長分析（按產品、按目標、按適應症、按人口統計、按最終用戶、按地區）：產業預測（2024-2031）

CAR T-Cell Therapy Market Size, Share, Growth Analysis, By Product (Yescarta, Kymriah), By Target (CD19, BCMA), By Indication, By Demographic, By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月14日 | 出版商:

SkyQuest | 英文 197 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球CAR-T細胞治療市場規模估值為52億美元，從2023年的72.7億美元成長到2031年的1060.6億美元，預計在預測期內（2024-2031年）將持續成長。複合年成長率為39.80%）。

預計全球癌症流行將在未來幾年顯著推動 CAR-T 細胞治療的需求。由於細胞研究投資的增加和基因工程技術的進步，CAR-T細胞治療市場預計將出現強勁成長。對個人化醫療的日益關注可能會進一步增加對 CAR-T 細胞療法的需求，特別是對於血癌，這將為該領域的服務提供者創造新的商機。此外，針對各種慢性疾病的創新 CAR-T 細胞療法的核准頻率不斷增加，支持了全球市場擴張的潛力。然而，也存在一些挑戰，例如治療成本上升、對安全性和副作用的擔憂以及患者接觸機會有限等。解決這些阻礙因素對於最大限度地發揮 CAR T 細胞療法的潛力並確保其覆蓋更廣泛的患者群體至關重要。隨著這種情況的發展，市場相關人員將需要考慮如何克服這些挑戰，同時利用技術進步和腫瘤學領域日益成長的未滿足的醫療需求帶來的新機會。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲 (MEA)
- 波灣合作理事會(GCC) 國家
- 南非
- 其他中東/非洲

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

諾華公司（瑞士）
強生公司（美國）
JW (Cayman) Therapeutics Co. Ltd.（開曼群島）
免疫過繼性細胞療法私人有限公司（Immunoact）（印度）
Carsgen Therapeutics Holdings Limited (中國)
IASO生物治療（中國）
廣州百基因科技有限公司（七喜集團股份有限公司）（中國）
Cartesian Therapeutics, Inc.（美國）
Autolus Therapeutics（英國）
同種異體療法（美國）
Crispr Therapeutics（瑞士）
烏根（美國）
Sangamo Therapeutics, Inc.（美國）
藍鳥生物公司（美國）
TCR2 Therapeutics Inc.（美國）
Genocea Biosciences, Inc.（美國）
Blairex Laboratories, Inc.（美國）
Medigene AG（德國）
Athenex, Inc.（美國）
Zymeworks Inc.（加拿大）
Regenxbio Inc.（美國）

簡介目錄

Product Code: SQMIG35H2300

Global CAR T-Cell Therapy Market size was valued at USD 5.2 billion in 2022 and is poised to grow from USD 7.27 billion in 2023 to USD 106.06 billion by 2031, growing at a CAGR of 39.80% during the forecast period (2024-2031).

The global cancer epidemic is anticipated to significantly drive the demand for CAR T-cell therapy in the upcoming years. With rising investments in cell research and advancements in genetic engineering technologies, the CAR T-cell therapy market is poised for robust growth. The increasing emphasis on personalized medicine is likely to further propel demand for CAR T-cell treatments, particularly in addressing blood cancer indications, which presents new opportunities for service providers in this field. Additionally, the growing frequency of approvals for innovative CAR T-cell therapies aimed at various chronic conditions underscores the expanding market potential on a global scale. However, the market faces challenges, including the high costs associated with treatment, concerns regarding procedural safety and potential side effects, as well as limited accessibility for patients. Addressing these restraints will be critical for unlocking the full potential of CAR T-cell therapies and ensuring they reach broader patient populations. As the landscape evolves, stakeholders in the CAR T-cell therapy market must navigate these challenges while capitalizing on emerging opportunities presented by technological advancements and increasing unmet medical needs in oncology.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Car T-Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Car T-Cell Therapy Market Segmental Analysis

Global CAR T-Cell Therapy Market is segmented by Product, Target, Indication, Demographic, End User, and region. Based on Product, the market is segmented into Yescarta, Kymriah, Carvykti, Abecma, Tecartus, Breyanzi, and Other Products. Based on Target, the market is segmented into CD19, BCMA, and Other Targets. Based on Indication, the market is segmented into Multiple Myeloma, B-Cell Lymphoma, Acute Lymphoblastic Leukemia, and Other Indications. Based on Demographic, the market is segmented into Adults, and Pediatrics. Based on End User, the market is segmented into Hospitals, Specialty Centers, and Long-Term Care Facilities. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Car T-Cell Therapy Market

The surge in personalized medicine is a significant market driver for the Global CAR T-Cell Therapy market, as it aligns closely with the growing demand for tailored healthcare solutions. As patients increasingly seek individualized treatment options, the ability of CAR T-cell therapy to be customized for each patient's unique tumor characteristics enhances its efficacy and appeal. This personalization not only improves therapeutic outcomes but also fosters patient engagement and adherence to treatment protocols. Consequently, the broader acceptance and integration of personalized medicine within oncology are expected to propel the CAR T-cell therapy market, leading to innovative advancements and expanding clinical applications in the coming years.

Restraints in the Global Car T-Cell Therapy Market

One significant market restraint for the Global CAR T-Cell Therapy market is the lingering uncertainty surrounding the long-term safety and potential side effects associated with this innovative treatment. Despite rigorous testing, concerns about adverse reactions, such as cytokine release syndrome and neurotoxicity, can lead to apprehension among patients and healthcare providers, ultimately hindering widespread adoption. Additionally, the complexity of administering CAR T-cell therapy and the requirement for specialized medical personnel and infrastructure further complicate its integration into standard cancer treatment protocols. This combination of safety concerns and logistical challenges may slow the growth of the CAR T-cell therapy market over the forecast period.

Market Trends of the Global Car T-Cell Therapy Market

The global CAR T-cell therapy market is witnessing a significant trend towards the development of allogeneic therapies, which utilize genetically modified T-cells derived from healthy donors rather than the patient's own cells. This innovation is driven by the potential for off-the-shelf treatment options that can provide quicker, more accessible solutions for patients with hematologic malignancies and solid tumors. With advancements in gene-editing technologies and the growing emphasis on reducing manufacturing complexities and costs, allogeneic CAR T-cell therapies are expected to gain traction, fostering increased investment and collaboration within the biopharmaceutical landscape. This shift promises to enhance patient outcomes while expanding market reach.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Value Chain Analysis
Technology Analysis
Patent Analysis
Pricing Analysis
Regulatory Landscape
Customer & Buying Criteria Analysis

Car T-Cell Therapy Market by Product

Market Overview
Yescarta
Kymriah
Carvykti
Abecma
Tecartus
Breyanzi
Other Products

Car T-Cell Therapy Market by Target

Market Overview
CD19
BCMA
Other Targets

Car T-Cell Therapy Market by Indication

Market Overview
Multiple Myeloma
B-Cell Lymphoma
Acute Lymphoblastic Leukemia
Other Indications

Car T-Cell Therapy Market by Demographic

Market Overview
Adults
Pediatrics

Car T-Cell Therapy Market by End User

Market Overview
Hospitals
Specialty Centers
Long-Term Care Facilities

Car T-Cell Therapy Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
JW (Cayman) Therapeutics Co. Ltd. (Cayman Islands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Immunoadoptive Cell Therapy Private Limited (Immunoact) (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Carsgen Therapeutics Holdings Limited (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
IASO Biotherapeutics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guangzhou Bio-Gene Technology Co., Ltd (Hedy Group Co., Ltd.) (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cartesian Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Autolus Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allogene Therapeutics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Crispr Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Wugen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sangamo Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
TCR2 Therapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genocea Biosciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Blairex Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medigene AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Athenex, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zymeworks Inc. (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenxbio Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments